Summary
Summary Heart Failure Key Clinical Trials
- Course
- PHARM 223 (PHARM223)
- Institution
- University Of Waterloo (UW )
Summary tables including all the clinical trials (PICO, results, bottom line) for Heart Failure
[Show more]
Seller
Follow
Content preview
Study Name Population Intervention Comparison Outcomes Follow-up Results BottomlineMA of ACEi in HF 54,621 All-cause Proportional
16 trials randomized HF mortality: reduced effects
participants, RAAS by 11% (RR 0.89, decreased with
inhibition risks for 95% CI 0.85-0.92) increasing mean
Cardiovascular
HF LVEF for all
Mortality: reduced
by 14% (RR 0.86, outcomes. There
95% CI 0.83-0.90) was still a
Hospitalization for decrease in the
HF: reduced by risk for HF
20% (RR 0.80, 95% hospitalization in
CI 0.77-0.83) patients with
preserved LVEF
SAVE 2231 patients with Captopril (initial Placebo All-cause ~42 months All-cause Established the
LVD (LVEF 40%) 6.25-12.5mg; mortality, CV mortality: RRR benefit of ACEi
beginning 3-16 target 25mg) death, 19%; P=0.0019 in post-MI
days post-MI hospitalization for CV Death: RRR. patients who
12%, P=0.014
HF, rMI, have EF 40%
Hospitalization for
symptomatic HF HF: RRR22%;
P=0.019
Recurrent MI: RRR
25%; P=0.0015
Symptomatic HF:
RRR 37%; P<0.001
SOLVED- 2569 patients with Enalapril (2.5 to Placebo All-cause 41.4 months All-cause Established the
treatment NYHA (regardless 20mg /day) mortality, mortality: absolute benefits of ACEi
of MI) Class II and hospitalization or risk reduced by in all sx HF
III HF death from HF 4.5% (NNT=23; patients
P=0.0036)
regardless of MI
Hospitalization or
death from HF: status
absolute risk
reduced by 9.6%
(NNT=11;
P<0.0001)
SOLVED- 4226 patients with Enalapril (2.5- Placebo All-cause 37.4 months No reduction in Even if the
prevention asymptomatic LV 20mg/day) mortality, CV total/CV death patient is
dysfx (LVEF <0.35) death, asymptomatic
hospitalizations Hospitalization for there are still
HF/death: ARR benefits of using
3.9%; NNT=26 ACEi if they have
, low EF
ATLAS (low v. 3164 patients with 32.5-35mg 2.5-5mg All-cause 46 months High dose reduced Want to get
high dose ACEi) NYHA Class II-IV Lisinopril Lisinopril mortality/hospital the combined patient to high
CHF (LVEF <30%) admissions endpoints of all- dose (safely) so
cause mortality that they can
Composite endpoints: and hospital benefit i.e., high
all-cause mortality + admission (RRR dose was better
hospitalization for HF; 12%; P=0.002)
CV death + Other endpoints
hospitalization for CV;
were also
fata/non-fatal MI +
hospitalization for UA reduced.
MERIT-HF 3991 patients with Metoprolol Cr/XL Placebo All-cause 1 year (stopped Endpoints were
NYHA Class II-IV. start 12.5-25mg, mortality early) lower in
(LVEF <40%) target to 200mg intervention group
daily compared to
placebo (RR 0.66
[95% CI 0.52-
0.81]; P=0.0009)
COPERNICUS 2289 patients who Carvedilol 3.125mg Placebo Mortality, 10.4 months 35% reduction in
had symptoms of BID (target 25mg mortality, or death
HF at rest or on PO BID) hospitalization 24% reduction in
minimal exertion death or
(LVEF <25%) hospitalization
(p<0.05)
COMET 1511 patients with Carvedilol (target Metoprolol All-cause 58 months All-cause Carvedilol better
NYHA Class II-IV 25mg BID) tartrate (short mortality, CV mortality: ARR 6% than metoprolol
CHF (mean LVEF acting) (target mortality/hospital for Carvedilol
0.26) 50mg BID) admission (NNT=17; Issues: metoprolol
P=0.0017) tartrate is not
comparable to 24h B1-
receptor blockade;
difference in HR
reduction may explain
difference in outcome
COMES 4016 patients with Carvedilol or metoprolol succinate 17,672 patient- After multivariable No conclusive
observational study stable systolic CHF (Individually matched on both dose- years adjustments (HR association
equivalents and the respective 0.93; 95% CI 0.57-
propensity score for BB treatment) 1.50; P=0.75)
CHARM- 2028 patients with Candesartan Placebo CV death/HF 33.7 months ARR 7%
symptomatic HF and LVEF
Alternative <40% not taking ACEi bc of (target dose 32mg) hospital NNT 14
prior intolerance admission
VAL-HeFT 5010 patients with Valsartan Placebo Primary outcome: 27 months Mortality was the Sub-analysis:
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller mariawasfy. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for CA$15.92. You're not tied to anything after your purchase.
Can Stuvia be trusted?
4.6 stars on Google & Trustpilot (+1000 reviews)
56326 documents were sold in the last 30 days
Founded in 2010, the go-to place to buy study notes for 14 years now